Skip to content

Partnering With a Specialty Pharmacy

Support Every Step of the Way

The Specialty Pharmacy helps with various aspects of treatment, such as:

  • Helping patients get access to Orenitram
  • Scheduling nurse visits to get patients started on therapy
  • Coordinating the delivery of medicine
  • Offering ongoing assistance through in-person or virtual visits and 24-hour phone support

Orenitram Is Only Available Through 2 Specialty Pharmacy Providers

ACCREDO

P: 1-866-344-4874

F: 1-800-711-3526

CVS

P: 1-877-242-2738

F: 1-877-943-1000

Download, complete, and fax the Referral Form to the SP of your choice so your patients can receive support while taking Orenitram.

Download Form
View Example Form >
iAssist logo

iAssist: Simplify the Process of
Getting Patients Started

With just a few clicks, your office can leverage the iAssist platform, which may minimize delays in therapy initiation for your patients.

iAssist is a complimentary, comprehensive solution that simplifies the complex process of getting patients on specialty therapy. With iAssist, healthcare professionals gain access to:

  • Electronic prescriptions and Referral Forms
  • Advanced benefit verifications
  • Real-time electronic prior authorizations
  • Patient electronic consent
  • Portal notifications that track patient adherence to therapy
  • Real-time e-support
Access iAssist >

Additional Support Resources

Cost and Financial Support

See how United Therapeutics may help with cost assistance and support for patients taking Orenitram.

Archways Program

Discover how a United Therapeutics Virtual Patient Educator may help your patients get started on Orenitram.

Video and Resource Library

To access helpful videos, downloadable resources for patients, and recent publications, visit Video and Resource Library.

SP=Specialty Pharmacy.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

IMPORTANT SAFETY INFORMATION

Contraindications

  • Avoid use of Orenitram in patients with severe hepatic impairment (Child Pugh Class C) due to increases in systemic exposure.

Warnings and Precautions

  • Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms.
  • The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum.

Adverse Reactions

  • In the 12-week, placebo-controlled, monotherapy study, and an event-driven placebo-controlled, combination therapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, vomiting, flushing, pain in jaw, pain in extremity, hypokalemia, abdominal discomfort, and upper abdominal pain.

Drug Interactions

  • Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients.

Specific Populations

  • Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies with Orenitram in pregnant women.
  • It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.
  • Safety and effectiveness of Orenitram in pediatric patients have not been established.
  • Use of Orenitram in patients aged 65 years and over demonstrated slightly higher absolute and relative adverse event rates compared to younger patients. Caution should be used when selecting a dose for geriatric patients.
  • There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients.

INDICATION

Orenitram is a prostacyclin mimetic indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

OREISIhcpOCT19

Please see Full Prescribing Information and Patient Information for Orenitram.

For additional information, call 1-877-UNITHER (1-877-864-8437).